Alectinib

Drug Overview

Alectinib is a highly selective and potent second-generation tyrosine kinase inhibitor (TKI) that targets Anaplastic Lymphoma Kinase (ALK). It is a standard-of-care therapy for a specific genetic subset of non-small cell lung cancer (NSCLC), offering superior efficacy and central nervous system (CNS) penetration compared to first-generation inhibitors like crizotinib.

• Generic Name: Alectinib
• US Brand Names: Alecensa®
• Drug Class: Kinase Inhibitor (ALK Inhibitor)
• Route of Administration: Oral (Capsules)
• FDA Approval Status: Approved for metastatic ALK-positive NSCLC (first-line and subsequent) and adjuvant treatment of resected ALK-positive NSCLC.

What Is It and How Does It Work? (Mechanism of Action)

Alectinib works by blocking the signals that drive the growth of cancer cells harboring specific genetic rearrangements.

• Molecular Target: The drug selectively inhibits the enzymatic activity of the Anaplastic Lymphoma Kinase (ALK) and RET tyrosine kinases.
• Inhibition of Signaling: In cancers with ALK gene rearrangements (most commonly EML4-ALK), the ALK protein is permanently “on,” driving uncontrolled cell growth. Alectinib binds to the ATP-binding pocket of the ALK kinase domain, preventing phosphorylation and downstream signaling (via STAT3 and AKT pathways).
• CNS Penetration: Unlike crizotinib, alectinib is not a substrate for P-glycoprotein (P-gp), a pump that ejects drugs from the brain. This allows alectinib to cross the blood-brain barrier effectively and achieve high concentrations in the central nervous system, treating and preventing brain metastases.

FDA-Approved Clinical Indications

Alectinib is FDA-approved for adult patients with ALK-positive non-small cell lung cancer (NSCLC).

Oncological Uses:

• First-Line Metastatic NSCLC: Treatment of patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.
• Previously Treated Metastatic NSCLC: Treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
• Adjuvant Treatment: Treatment of patients with ALK-positive NSCLC following tumor resection (tumors ≥4 cm or node-positive).

Non-Oncological Uses:

• There are no FDA-approved non-oncological indications.

Dosage and Administration Protocols

Alectinib is an oral medication taken twice daily. It must be taken with food to ensure proper absorption.

Standard Oncology Dosage:

• Dose: 600 mg (four 150 mg capsules) twice daily.
• Frequency: Every 12 hours.
• Food Requirement: Must be taken with food.

Dose Modifications for Toxicity:

• First Reduction: 450 mg twice daily.
• Second Reduction: 300 mg twice daily.
• Discontinue: If patients cannot tolerate 300 mg twice daily.

Clinical Efficacy and Research Results

Clinical data from 2020-2025 demonstrate alectinib’s long-term survival benefits and its new role in early-stage disease.

• Overall Survival (ALEX Trial): Updated data (2024-2025) show a median Overall Survival (OS) of 81.1 months with alectinib versus 54.2 months with crizotinib in the first-line metastatic setting. This represents a substantial, durable survival benefit.
• Adjuvant Efficacy (ALINA Trial): In patients with resected stage IB-IIIA ALK-positive NSCLC, adjuvant alectinib reduced the risk of disease recurrence or death by 76% compared to platinum-based chemotherapy. At 2 years, 93.8% of patients in the alectinib arm were disease-free compared to 63% in the chemotherapy arm.
• CNS Efficacy: Alectinib significantly delays the time to CNS progression. In the ALEX trial, the time to CNS progression was notably longer than with crizotinib, confirming its potent protective effect on the brain.

Safety Profile and Side Effects

Important Warnings:

Alectinib carries warnings for Hepatotoxicity, Interstitial Lung Disease (ILD), Bradycardia, Severe Myalgia, and Hemolytic Anemia.

Common Side Effects (>20%)

• Gastrointestinal: Constipation (very common), nausea, diarrhea, and vomiting.
• General: Fatigue and edema (swelling of hands/feet/face).
• Musculoskeletal: Myalgia (muscle pain) and increased Creatine Phosphokinase (CPK) levels.
• Dermatologic: Rash and photosensitivity.

Serious Adverse Events

• Hepatotoxicity: Elevations in ALT, AST, and bilirubin can be severe. Liver function must be monitored every 2 weeks for the first 3 months.
• Interstitial Lung Disease (ILD): Pneumonitis occurred in ~1.3% of patients. Permanent discontinuation is required if ILD is confirmed.
• Bradycardia: Symptomatic slow heart rate may occur. Heart rate and blood pressure monitoring are required.
• Hemolytic Anemia: Breakdown of red blood cells can occur; if suspected, withhold the drug and test.

Management Strategies:

• For Bradycardia: If symptomatic, hold the drug; concomitant medications (beta-blockers) may need adjustment.
• For Myalgia: Monitor CPK levels every 2 weeks for the first month. Temporarily withhold for severe elevation (>5x ULN).

Connection to Stem Cell and Regenerative Medicine

Alectinib interacts with the molecular drivers that can fuel cancer stem cell survival in ALK-driven tumors.

• Targeting ALK-Addicted Stem Cells: In neuroblastoma and NSCLC models, ALK signaling is crucial for the survival of “tumor-initiating cells” or cancer stem cells. Alectinib’s potent inhibition of ALK can eradicate these stem-like populations more effectively than crizotinib, potentially preventing relapse.
• Bridge to Transplant (Lymphoma): In rare cases of ALK-positive Anaplastic Large Cell Lymphoma (ALCL), alectinib has been used as a “bridge” to induce deep remission, allowing patients to proceed to a curative Allogeneic Stem Cell Transplant when other therapies failed.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• ALK Mutation Testing: Mandatory FDA-approved test to confirm ALK positivity.
• Liver Function Tests: Baseline ALT, AST, and Bilirubin.
• CPK Levels: Baseline Creatine Phosphokinase to monitor for muscle toxicity.
• Pregnancy Test: Verify negative status in females of reproductive potential.

Precautions During Treatment:

• Sun Protection: Patients should avoid sun exposure and use sunscreen/protective clothing during treatment and for 7 days after the last dose to prevent photosensitivity reactions.
• Heart Rate Monitoring: Regular checks for bradycardia are advised.

Do’s and Don’ts:

• DO: Take the medication with food to ensure it works effectively.
• DO: Report unexplained muscle pain, tenderness, or weakness immediately (signs of CPK elevation).
• DON’T: Breastfeed during treatment and for 1 week after the final dose.
• DON’T: Crush or dissolve the capsules; swallow them whole.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.